Download Celgene Reports Results from the Phase III POSTURE

MEDIA RELEASE
For more information
Newsroom
Businesswire Australia and New Zealand
[email protected]
10-Jul-2014 8:26 AM
Topic: Health
Celgene Reports Results from the Phase III POSTURE
Study Evaluating Oral OTEZLA® in Ankylosing
Spondylitis
Phase III POSTURE Study Did Not Achieve Primary Endpoint of ASAS 20 at Week 16
Based on Efficacy and Safety Data at Week 24, the Independent Data Monitoring Committee Recommended
Continuation of the Phase III POSTURE Study Without Change
In OTEZLA Study Arms, ASAS 20 Results Continued to Improve Over Time
OTEZLA Tolerability and Safety Profile Consistent With Previous Clinical Trials
SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ:CELG) today announced results of its phase III
POSTURE study evaluating OTEZLA, the company's oral, selective inhibitor of phosphodiesterase 4 (PDE4), in
patients with active ankylosing spondylitis. The OTEZLA arms did not achieve statistically significant improvement
versus the placebo arm for the primary endpoint, the percentage of patients who achieve an ASAS (Assessment of
SpondyloArthritis international Society) 20 response at week 16. However, in a prespecified analysis, meaningful
efficacy was observed at Week 24 in a large subset of patients with early-stage disease. Evaluation of the efficacy
results is ongoing.
“We are encouraged by these preliminary results, especially in patients with shorter disease duration and based on
our evaluation and learnings from POSTURE, we plan to initiate another Phase III trial pending further data analysis,
including the 52-week MRI data”
An independent data monitoring committee (DMC) recommended that the study proceed unchanged, based on an
assessment of the safety and efficacy data at week 24. According to the protocol, magnetic resonance imaging
(MRI) data will be collected in a subgroup of subjects at week 52 and at additional time points, and radiographs will
be taken on all study patients at week 104 and at additional time points.
The safety and tolerability data observed in the POSTURE study are consistent with previously reported phase II
data in ankylosing spondylitis, as well as six phase III studies of OTEZLA in psoriatic arthritis or psoriasis. No new
safety signals were observed.
“We are encouraged by these preliminary results, especially in patients with shorter disease duration and based on
our evaluation and learnings from POSTURE, we plan to initiate another Phase III trial pending further data analysis,
including the 52-week MRI data,” said Scott Smith, Global Head of Inflammation & Immunology at Celgene
Corporation. “Ankylosing spondylitis is a chronic, debilitating disease, and despite advances over the last 15 years,
there remains significant unmet need for a safe, effective, oral therapy—especially for patients early in the
progression of their disease.”
The evaluation of safety and efficacy in the treatment arms is ongoing and the results of the study will be presented
at an upcoming medical meeting.
These results are from an investigational phase III study. OTEZLA is not approved for the treatment of patients with
ankylosing spondylitis in any country.
About POSTURE
POSTURE is a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate
the efficacy and safety of OTEZLA (apremilast), the Company's oral, selective inhibitor of phosphodiesterase 4
(PDE4), in the treatment of active ankylosing spondylitis. The primary endpoint of the study is the proportion of
subjects in each treatment group who achieve an ASAS (Assessment of SpondyloArthritis internationalSociety) 20
response, defined as an improvement for patients of at least 20%, at week 16. Secondary endpoints include other
measures of function, disease activity, and quality of life. In POSTURE, 490 subjects were randomized in a 1:1:1
ratio to receive either apremilast 20 mg BID, apremilast 30 mg BID, or identically-appearing placebo for 24 weeks,
with a subsequent long-term extension phase in which all subjects are treated with apremilast. The POSTURE study
includes adult subjects who have a diagnosis of “definite AS” as defined by the modified New York criteria (1984);
have symptoms of active disease based on a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of
= 4; and have a Total Back Pain Numerical Rating Scales (NRS) score of =4. Subjects can take nonsteroidal antiinflammatory drug (NSAID) therapies, disease-modifying anti-rheumatic drugs (DMARDs) or low-dose
corticosteroids, as long as they are on a stable dose of these agents prior to baseline and remain on these agents at
the same doses through the 24-week placebo-controlled phase. Subjects must not have prior treatment with a tumor
necrosis factor (TNF) blocker or any biologic treatment for AS.
About OTEZLA
OTEZLA is an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine
monophosphate (cAMP). PDE4 inhibition results in increased intracellular cAMP levels. OTEZLA was approved on
March 21, 2014 by the U.S. Food and Drug Administration (FDA) for the treatment of adults with active psoriatic
arthritis. A combined psoriatic arthritis/psoriasis Marketing Authorization Application (MAA) in Europe was submitted
to health authorities in the fourth quarter of 2013. To learn more about OTEZLA visit www.otezla.com.
IMPORTANT SAFETY INFORMATION
INDICATION
OTEZLA® (apremilast) is indicated for the treatment of adult patients with active psoriatic arthritis.
Contraindications
OTEZLA is contraindicated in patients with a known hypersensitivity to apremilast or to any of the excipients in the
formulation.
Warnings and Precautions
Depression: Treatment with OTEZLA is associated with an increase in adverse reactions of depression. During
clinical trials, 1.0% (10/998) of patients treated with OTEZLA reported depression or depressed mood compared to
0.8% (4/495) treated with placebo; 0.3% (4/1441) of patients treated with OTEZLA discontinued treatment due to
depression or depressed mood compared with none in placebo treated patients (0/495). Depression was reported
as serious in 0.2% (3/1441) of patients exposed to OTEZLA, compared to none in placebo treated patients (0/495).
Suicidal ideation and behavior were observed in 0.2% (3/1441) of patients on OTEZLA, compared to none on
placebo (0/495). Two patients who received placebo committed suicide compared to none on OTEZLA.
Carefully weigh the risks and benefits of treatment with OTEZLA for patients with a history of depression and/or
suicidal thoughts/behavior, or in patients who develop such symptoms while on OTEZLA. Patients, caregivers, and
families should be advised of the need to be alert for the emergence or worsening of depression, suicidal thoughts
or other mood changes, and they should contact their healthcare provider if such changes occur.
Weight Decrease: Body weight loss of 5-10% was reported in 10% of patients taking OTEZLA and in
3.3% of patients taking placebo. Monitor body weight regularly; evaluate unexplained or clinically significant weight
loss, and consider discontinuation of OTEZLA.
Drug Interactions: Apremilast exposure was decreased when OTEZLA was co-administered with rifampin, a strong
CYP450 enzyme inducer; loss of OTEZLA efficacy may occur. Concomitant use of OTEZLA with CYP450 enzyme
inducers (eg, rifampin, phenobarbital, carbamazepine, phenytoin) is not recommended.
Adverse Reactions
Adverse reactions reported in at least 2% of patients taking OTEZLA, that occurred at a frequency at least 1%
higher than that observed in patients taking placebo, for up to 16 weeks (after the initial 5-day titration), were
(OTEZLA%, placebo%): diarrhea (7.7, 1.6); nausea (8.9, 3.1); headache (5.9, 2.2); upper respiratory tract infection
(3.9, 1.8); vomiting (3.2, 0.4); nasopharyngitis (2.6, 1.6); upper abdominal pain (2.0, 0.2).
Use in Specific Populations
Pregnancy and Nursing Mothers: OTEZLA is Pregnancy Category C; it has not been studied in pregnant women.
Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether
apremilast or its metabolites are present in human milk. Caution should be exercised when OTEZLA is administered
to a nursing woman.
Renal Impairment: OTEZLA dosage should be reduced in patients with severe renal impairment (creatinine
clearance less than 30 mL/min); for details, see Dosage and Administration, Section 2, in the Full Prescribing
Information.
Please click here for Full Prescribing Information.
About Celgene
Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company
engaged primarily in the discovery, development and commercialization of novel therapies for the treatment of
cancer and inflammatory diseases through gene and protein regulation. For more information, please
visit www.celgene.com. Follow us on Twitter @Celgene as well.
Forward-Looking Statements
This press release contains forward-looking statements, which are generally statements that are not historical facts.
Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends,"
"estimates," "plans," "will," “outlook” and similar expressions. Forward-looking statements are based on
management's current plans, estimates, assumptions and projections, and speak only as of the date they are made.
We undertake no obligation to update any forward-looking statement in light of new information or future events,
except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of
which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially
from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which
are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and
Exchange Commission.
Contacts
Celgene Corporation
Investors:
908-673-9628
[email protected]
or
Media:
908-673-2275
[email protected]
About Businesswire
Tens of thousands of communications and organisations around the world trust Business Wire to issue their press
releases, multimedia and regulatory filings to news media, digital platforms, regulatory authorities and industry
influencers. With thousands of distribution and targeting options that reach 162 countries in 50+ languages and 193
industry trade categories, Business Wire gives you access to the world's most powerful press release network. Built
on our patented simultaneous and secure NX network and augmented with partnerships with international and
national news agencies, Business Wire is a valued and trusted source for breaking news by reporters, investors and
consumers. Founded in 1961, Business Wire has 32 bureaus around the globe and is a fully owned subsidiary of
Berkshire Hathaway, a Fortune 5 company.
On Twitter: businesswire
On LinkedIn: http://www.linkedin.com/company/business-wire
More from Business Wire Australia and New Zealand
Get the latest media releases, subscribe to release alerts, and download print and web ready media files at:
http://www.newsboost.com/newsroom/businesswire